Recent breakthroughs in cancer immunotherapy highlight a surge of innovation targeting lung and pancreatic cancers. Novel agents such as bispecific antibodies combining PD-1 blockade with VEGF inhibition have received regulatory approval, expanding therapeutic options for resistant tumors. Concurrently, clinical collaborations harness AI-driven tumor data analytics to identify predictive biomarkers, improving patient stratification and response evaluation. These advances strengthen the growing integration of precision immunotherapies coupled with computational modeling, propelling oncology towards more personalized and effective treatments.